[HTML][HTML] COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
AM Šola, IC Kurolt, ŽM Šafranko - Transfusion clinique et biologique, 2021 - Elsevier
Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - … et Biologique: Journal …, 2021 - europepmc.org
Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …
[PDF][PDF] COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlic, AM Šola, B Halassy, J Šemnicki… - 2021 - researchgate.net
abstract Objectives.–The patients with hematological malignancies are a vulnerable group
to COVID-19, due to the immunodeficiency resulting from the underlying disease and …
to COVID-19, due to the immunodeficiency resulting from the underlying disease and …
[HTML][HTML] COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - Transfusion Clinique …, 2021 - ncbi.nlm.nih.gov
Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola… - … : journal de la …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - Annual meeting of the …, 2021 - croris.hr
Sažetak The patients with hematological malignancies are a vulnerable group to COVID-19,
due to the immunodeficiency resulting from the underlying disease and oncological …
due to the immunodeficiency resulting from the underlying disease and oncological …
[引用][C] COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - Transfusion Clinique et …, 2021 - cir.nii.ac.jp
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - … et Biologique: Journal …, 2021 - europepmc.org
Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
D Rnjak, S Ravlić, AM Šola, B Halassy… - Transfusion clinique et …, 2021 - croris.hr
Objectives: The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …
19, due to the immunodeficiency resulting from the underlying disease and oncological …